- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05848713
Antitrombotisk terapi for å lindre kliniske komplikasjoner ved fellesskapservervet lungebetennelse (ATTACC-CAP)
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The global incidence of hospitalization due to CAP is high and associated with substantive morbidity and mortality. Thrombotic complications - including venous, arterial, and possibly microvascular - occur commonly in hospitalized patients across many etiologies of CAP. Poor outcomes may be mediated by both inflammatory and thrombotic processes leading to respiratory, cardiac, and other end organ dysfunction. There are currently no established therapies that modify the potentially maladaptive immunothrombosis pathway in CAP.
Therapeutic-dose anticoagulation with heparin reduces disease progression and mortality in non-critically ill patients hospitalized with COVID-19 with an acceptable safety profile. COVID-19 shares pathogenic features, including activation of the inflammatory and coagulation cascades, with other pneumonias. Whether therapeutic-dose heparin confers similar clinical benefits in non-COVID-19 CAP is unknown.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Chantale Pineau
- Telefonnummer: 2042353223
- E-post: attacc.cap@umanitoba.ca
Studiesteder
-
-
Espírito Santo
-
Serra, Espírito Santo, Brasil, 29166-828
- Rekruttering
- Hospital Estadual Dr. Jayme Santos Neves
-
Ta kontakt med:
- Marcus Matos, MD
-
Hovedetterforsker:
- Marcus Matos, MD
-
Vila Velha, Espírito Santo, Brasil
- Rekruttering
- Hospital Evangelico de Vila Velha
-
Ta kontakt med:
- Joao Moraes Junior, MD
-
Hovedetterforsker:
- Joao Moraes Junior, MD
-
Hovedetterforsker:
- Guiherme Fonseca, MD
-
-
Estado de Bahia
-
Itabuna, Estado de Bahia, Brasil
- Fullført
- Santa Casa de Misericordia de Itabuna
-
-
Federal District
-
Brasília, Federal District, Brasil
- Fullført
- Hospital Brasilia
-
Brasília, Federal District, Brasil
- Fullført
- Instituto de Cardiologia e Transplantes do Distrito Federal
-
-
Goiás
-
Goiânia, Goiás, Brasil
- Rekruttering
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
-
Ta kontakt med:
- Sandra Nivea dos Reis Saraiva, MD
-
Hovedetterforsker:
- Sandra Falcao, MD
-
Goiânia, Goiás, Brasil
- Rekruttering
- Hospital Ruy Azeredo
-
Ta kontakt med:
- Rafael Bastos, MD
-
Hovedetterforsker:
- Rafael Bastos, MD
-
Goiânia, Goiás, Brasil
- Rekruttering
- Instituto Goiano de Oncologia e Hematologia - INGOH
-
Ta kontakt med:
- Mayler Santos, MD
-
Hovedetterforsker:
- Mayler Santos, MD
-
-
Mato Grosso do Sul
-
Campo Grande, Mato Grosso do Sul, Brasil
- Rekruttering
- Hospital São Julião
-
Ta kontakt med:
- Maurício Pompílio Pompílio, MD
-
Campo Grande, Mato Grosso do Sul, Brasil
- Rekruttering
- Santa Casa de Campo Grande
-
Ta kontakt med:
- Eduardo Calvoso, MD
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil
- Fullført
- Hospital Felicio Rocho
-
Belo Horizonte, Minas Gerais, Brasil
- Fullført
- NUPEC-Orizonti
-
Belo Horizonte, Minas Gerais, Brasil
- Rekruttering
- Santa Casa de Misericórdia de Belo Horizonte
-
Ta kontakt med:
- Claudio Dornas, MD
-
Uberaba, Minas Gerais, Brasil
- Rekruttering
- Hospital das Clínicas da Universidade Federal do Triângulo Mineiro
-
-
Paraná
-
Campo Largo, Paraná, Brasil, 83606-177
- Rekruttering
- Hospital do Rocio
-
Ta kontakt med:
- CESAR DUSILEK, MD
-
Curitiba, Paraná, Brasil
- Rekruttering
- Hospital Santa Cruz
-
Ta kontakt med:
- Marcelo Carneiro, MD
-
Hovedetterforsker:
- Marcelo Carneiro, MD
-
Curitiba, Paraná, Brasil
- Fullført
- PUCPR
-
-
Rio Grande do Sul
-
Lajeado, Rio Grande do Sul, Brasil
- Rekruttering
- Hospital Bruno Born
-
Ta kontakt med:
- Lucas Mallmann, MD
-
Hovedetterforsker:
- Lucas Mallmann, MD
-
Passo Fundo, Rio Grande do Sul, Brasil
- Rekruttering
- Hospital Sao Vicente de Paulo
-
Ta kontakt med:
- Alexandre Tognon, MD
-
Hovedetterforsker:
- Alexandre Tognon
-
Porto Alegre, Rio Grande do Sul, Brasil
- Rekruttering
- Hospital de Clínicas de Porto Alegre
-
Ta kontakt med:
- Paulo Dalcin, MD
-
Hovedetterforsker:
- Paulo Dalcin, MD
-
Santa Maria, Rio Grande do Sul, Brasil
- Fullført
- Hospital Universitario de Santa Maria
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasil
- Rekruttering
- Hospital Clementino Fraga Filho - UFRJ
-
Ta kontakt med:
- Fernanda Mello
-
-
Santa Catarina
-
Criciúma, Santa Catarina, Brasil
- Rekruttering
- Hospital Sao Jose
-
Ta kontakt med:
- Felipe Pizzol, MD
-
Hovedetterforsker:
- Felipe Pizzol, MD
-
-
South Carolina
-
São José, South Carolina, Brasil
- Fullført
- Hospital Regional Homero Miranda Gomes
-
-
São Paulo
-
Botucatu, São Paulo, Brasil
- Rekruttering
- UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
-
Ta kontakt med:
- Suzana Erico Tanni, MD
-
Hovedetterforsker:
- Suzana Erico Tanni, MD
-
Bragança Paulista, São Paulo, Brasil
- Rekruttering
- Hospital Universitario Sao Francisco na Providencia na Deus
-
Ta kontakt med:
- Gustavo Mamprin, MD
-
Hovedetterforsker:
- Gustavo Mamprin, MD
-
Campinas, São Paulo, Brasil
- Rekruttering
- IPECC
-
Ta kontakt med:
- Jose Francisco Kerr Saraiva, MD
-
Hovedetterforsker:
- Jose Francisco Kerr Saraiva, MD
-
Campinas, São Paulo, Brasil, 13083-190
- Rekruttering
- Fundação Centro Médico de Campinas
-
Ta kontakt med:
- Otavio Coelho, MD
-
Hovedetterforsker:
- Otavio Coelho, MD
-
Osasco, São Paulo, Brasil
- Rekruttering
- CiTen - Centro Hospital Municipal Antonio Giglio
-
Ta kontakt med:
- Enrico Fortunato, MD
-
Hovedetterforsker:
- Enrico Fortunato, MD
-
Presidente Prudente, São Paulo, Brasil
- Rekruttering
- Hospital Regional de Presidente Prudente
-
Ta kontakt med:
- Luis Felipe Pires, MD
-
Hovedetterforsker:
- Luis Felipe Pires, MD
-
Ribeirão Preto, São Paulo, Brasil
- Har ikke rekruttert ennå
- Hospital Estadual de Serrana
-
Ta kontakt med:
- Marcos Borges, MD
-
Hovedetterforsker:
- Marcos Borges, MD
-
São Paulo, São Paulo, Brasil, 05403-010
- Rekruttering
- HCFMUSP
-
Ta kontakt med:
- Ludhmila Hajjar, MD
-
Hovedetterforsker:
- Ludhmila Hajjar, MD
-
São Paulo, São Paulo, Brasil, 02189-010
- Rekruttering
- Hospital Nipo-Brasileiro
-
Ta kontakt med:
- Jose Victor Krasner Schubsky, MD
-
São Paulo, São Paulo, Brasil
- Fullført
- Santa Casa de Misericordia de Sao Paulo
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Rekruttering
- Foothills Medical Centre - Alberta Health Services
-
Ta kontakt med:
- Deepa Suryanarayan, MD
- Telefonnummer: 4039448167
- E-post: dsuryana@ucalgary.ca
-
Hovedetterforsker:
- Deepa Suryanarayan, MD
-
Grande Prairie, Alberta, Canada, T8V 4B1
- Har ikke rekruttert ennå
- Grand Prairie Regional Hospital
-
Ta kontakt med:
- Tafi Madzimure, MD
-
Hovedetterforsker:
- Tafi Madzimure, MD
-
-
British Columbia
-
Nanaimo, British Columbia, Canada
- Rekruttering
- Nanaimo Regional General Hospital
-
Ta kontakt med:
- Alistair Teale, MD
-
Hovedetterforsker:
- Alistair Teale, MD
-
Penticton, British Columbia, Canada
- Har ikke rekruttert ennå
- Penticton Regional Hospital
-
Ta kontakt med:
- Teresa Rodriguez, MD
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Rekruttering
- Vancouver General Hospital
-
Hovedetterforsker:
- Ted Steiner, MD
-
Ta kontakt med:
- Ted Steiner, MD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Rekruttering
- St. Boniface General Hospital
-
Ta kontakt med:
- Vi Dao, MD
-
Hovedetterforsker:
- Terry Wuerz, MD
-
Hovedetterforsker:
- Vi Dao, MD
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Rekruttering
- Health Sciences Center Winnipeg
-
Ta kontakt med:
- Brett Houstin, MD
-
Winnipeg, Manitoba, Canada
- Rekruttering
- Grace General Hospital
-
Ta kontakt med:
- Sylvain Lother, MD
- E-post: sylvain.lother@umanitoba.ca
-
Hovedetterforsker:
- Sylvain Lother, MD
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1C 5S7
- Rekruttering
- Memorial University
-
Ta kontakt med:
- Peter Daley, MD
-
Hovedetterforsker:
- Peter Daley, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 2H3
- Rekruttering
- Health Sciences North Research Institute
-
Ta kontakt med:
- Pandma Puranam, MD
-
Hovedetterforsker:
- Pandma Puranam, MD
-
Greater Sudbury, Ontario, Canada
- Rekruttering
- Health Sciences North ResearchInstitute (HSNRI)
-
Ta kontakt med:
- Pandma Puranam, MD
-
Hamilton, Ontario, Canada
- Rekruttering
- Hamilton Health Sciences
-
Ta kontakt med:
- Alison Fox-Robichaud, MD
-
Hovedetterforsker:
- Alison Fox-Robichaud, MD
-
Hamilton, Ontario, Canada
- Rekruttering
- Hamilton Health Sciences - Juravinski
-
Hovedetterforsker:
- Dominik Mertz, MD
-
Hovedetterforsker:
- Bram Rochwerg, MD
-
Ta kontakt med:
- Bram Rochwerg, MD
-
Markham, Ontario, Canada, L3P 7P3
- Rekruttering
- Markham Stouffville Hospital
-
Hovedetterforsker:
- Paul Lee, MD
-
Ta kontakt med:
- Paul Lee, MD
-
Hovedetterforsker:
- Janet Nguyen, MD
-
Ottawa, Ontario, Canada
- Rekruttering
- The Ottawa Hospital
-
Ta kontakt med:
- Lana Castellucci, MD
-
Ottawa, Ontario, Canada
- Rekruttering
- Hôpital Montfort
-
Ta kontakt med:
- Marc Carrier, MD
-
Saint Catherines, Ontario, Canada, L2S 0A9
- Rekruttering
- Niagara Health System - St Catharines Site
-
Ta kontakt med:
- Aidan Findlater, MD
- E-post: Aidan.Findlater@niagarahealth.on.ca
-
Hovedetterforsker:
- Aidan Findlater, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Rekruttering
- Sunnybrook Health Sciences Centre
-
Ta kontakt med:
- Jonathan Zipursky, MD
-
Hovedetterforsker:
- Jonathan Zipursky, MD
-
Toronto, Ontario, Canada
- Har ikke rekruttert ennå
- St. Michael's Hospital
-
Ta kontakt med:
- Michael Colacci, MD
-
-
Quebec
-
Montreal, Quebec, Canada
- Rekruttering
- Jewish General Hospital
-
Ta kontakt med:
- Susan Khan, MD
-
Ta kontakt med:
- Vicky Tagalakis, MD
-
Montreal, Quebec, Canada, H4A3J1
- Rekruttering
- McGill University Health Centre
-
Ta kontakt med:
- Emily Gibson McDonald, MD, MSc
-
Montreal, Quebec, Canada
- Rekruttering
- Centre Hospitalier de l'université de Montréal (CHUM)
-
Ta kontakt med:
- Emmanuelle Duceppe, MD
-
Québec, Quebec, Canada
- Rekruttering
- CHU de Quebec-University Laval
-
Ta kontakt med:
- Alexis Turgeon, MD, MSc
-
Québec, Quebec, Canada
- Rekruttering
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
Ta kontakt med:
- Francois Lallouche, MD
-
Sherbrooke, Quebec, Canada
- Rekruttering
- Centre Hospitalier Universitaire de Sherbrooke
-
Hovedetterforsker:
- Francois Lamontagne, MD
-
Ta kontakt med:
- Francois Lamontagne, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0W5
- Rekruttering
- Regina General Hospital
-
Hovedetterforsker:
- Payam Dehghani, MD
-
Ta kontakt med:
- Payam Dehghani, MD
-
Saskatoon, Saskatchewan, Canada
- Har ikke rekruttert ennå
- University of Saskatchewan
-
Ta kontakt med:
- Geroffrey Shumailak, MD
-
-
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Ta kontakt med:
- Jonathan Paul, MD
-
-
Louisiana
-
Jefferson, Louisiana, Forente stater, 70121
- Rekruttering
- Ochsner Clinic
-
Ta kontakt med:
- Derek Vondehaar, MD
-
-
Maine
-
Portland, Maine, Forente stater, 04102
- Rekruttering
- Maine Medical Centre
-
Ta kontakt med:
- Daniel Meyer, MD
-
Hovedetterforsker:
- Daniel Meyer, MD
-
-
Michigan
-
Dearborn, Michigan, Forente stater, 48128
- Fullført
- Henry Ford Health System
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Rekruttering
- Cooper University Health Care
-
Ta kontakt med:
- Adam Green, MD
-
Hovedetterforsker:
- Adam Green, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
Ta kontakt med:
- Alisha Sharma, MD
-
Hovedetterforsker:
- Alisha Sharma, MD
-
-
-
-
Mexico City
-
Mexico City, Mexico City, Mexico
- Rekruttering
- Hospital General Regional 1. Carlos MacGregor Sánchez Navarro
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients ≥18 years of age
-
Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
- Radiographic evidence of new or worsening infiltrate
- One or more of the following signs and/or symptoms of lower respiratory tract infection
i. New or increased cough or sputum production ii. Fever of > 37.8C or temperature < 36C iii. WBC > 11 x 109/L or < 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
-
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
-
Hospital admission anticipated to last ≥72 hours from randomization
Exclusion Criteria:
-
Suspected or confirmed active COVID-19 infection
-
Hospital admission for >72 hours prior to randomization
-
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
-
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
-
Patients for whom the intent is to not use pharmacologic thromboprophylaxis
-
Patients with an independent indication for therapeutic-dose anticoagulation
-
Patients with a contraindication to therapeutic-dose anticoagulation, including:
- Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
- History of an inherited or acquired bleeding disorder
- Cerebral aneurysm or mass lesions of the central nervous system
- Ischemic stroke within 3 months of hospital admission
- Gastrointestinal bleeding within 3 months of hospital admission
- Platelet count <50 x109/L OR INR >2.0 OR hemoglobin <80 g/L at the time of screening
- Other physician-perceived contraindications to therapeutic anticoagulation
-
History of heparin induced thrombocytopenia (HIT) or other heparin allergy
-
Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
-
Patients in whom imminent death is anticipated
-
Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
-
Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Therapeutic-Dose Heparin
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization. |
Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient. Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement. |
|
Ingen inngripen: Usual Care
Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ordinal endpoint reflecting survival
Tidsramme: 30 days
|
Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications. |
30 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Alle forårsaker dødelighet
Tidsramme: 30 dager, 90 dager og 180 dager
|
30 dager, 90 dager og 180 dager
|
|
|
Bleeding events
Tidsramme: 14 days
|
Number of participants with major bleeds as defined by the ISTH definition. |
14 days
|
|
HIT events
Tidsramme: 14 days
|
Number of participants with laboratory confirmed heparin induced thrombocytopenia (HIT) |
14 days
|
|
Thrombotic events
Tidsramme: 30 days and 90 days
|
Number of participants with deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke |
30 days and 90 days
|
|
Invasive mechanical ventilation
Tidsramme: 30 days
|
Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization |
30 days
|
|
Hospital-free days
Tidsramme: 30 days, 90 days, and 180 days
|
Days alive outside hospital |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Tidsramme: 30 days, 90 days, and 180 days
|
Using the EQ-5D-5L instrument |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Tidsramme: 30 days, 90 days, and 180 days
|
Using the Clinical Frailty Scale instrument |
30 days, 90 days, and 180 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Patrick Lawler, MD, University Health Network and McGill University
- Hovedetterforsker: Sylvain Lother, MD, University of Manitoba
- Hovedetterforsker: Alexis Turgeon, MD, L'Universite Laval
- Hovedetterforsker: Ryan Zarychanski, MD, University of Manitoba
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ATTACC-CAP
- OZM-129 (Annen identifikator: Ozmosis Research Inc.)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .